Freeslate has built strong capabilities around automated solutions addressing the complex problems of drug development and enabling dramatic gains in R&D productivity and innovation.
Sunnyvale, Calif. (PRWEB) October 20, 2011
Freeslate, Inc., the leading provider of high throughput research solutions, announced today that Amgen, Inc. has entered into a collaborative relationship with the company to leverage Freeslate solutions in addressing aggregation and particulation in protein drug products. The multi-year project will utilize a range of Freeslate products and services, including technology development, high throughput microscale workflows, and Freeslate’s Lab Execution and Analysis (LEA) software.
Freeslate was selected by Amgen for its depth of knowledge and experience in implementing solutions for solving the complex protein formulation challenges Amgen is facing. A tenured leader in the area of high throughput research, Freeslate has built strong capabilities around automated solutions addressing the complex problems of drug development and enabling dramatic gains in R&D productivity and innovation.
Freeslate’s integrated workflows are managed by its LEA software platform which creates a single, experimental environment that helps to accelerate scientific decision making and QbD initiatives.
“As illustrated by this relationship and others we have engaged in over the past year, the formulation of protein therapeutics is a pressing problem for pharmaceutical companies. High throughput research can enable significant steps forward in both understanding and addressing the challenges of aggregation and particulation in protein drug products,” said John Senaldi, CEO of Freeslate. “This is an application area where we are confident in our ability to deliver great value and innovation.”
Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, energy, and consumer products industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe and Asia. For more information, visit http://www.freeslate.com.